Company Overview
Exicure, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, which involves the discovery and development of biological therapies to address medical needs. The company's primary business focus has historically centered on the development of nucleic acid therapies designed to target ribonucleic acid against validated biological targets, although its current operational footprint is described as lacking significant active operations. As of the latest available data, Exicure, Inc. maintains a market capitalization of $28.14 million, while specific figures for annual revenue and employee count are not disclosed in the current financial records. This market capitalization indicates that Exicure is a small-cap entity, suggesting a limited scale of operations relative to large-cap pharmaceutical peers and reflecting the typical valuation characteristics of early-stage biotechnology firms that are often pre-revenue or in the research phase. The absence of reported employee data further underscores the company's minimal operational scale, positioning it as a micro-cap asset where valuation is driven almost entirely by potential intellectual property value rather than current production capacity or workforce size.
Financial Health
Exicure, Inc. reports a net income of $-4,946,000 over the trailing twelve months, while EBITDA stands at $-9,875,000, highlighting a significant financial burn rate typical of biotechnology companies in the development stage. The gross margin, operating margin, and profit margin are all recorded at 0.0%, a figure that reveals a cost structure where expenses vastly exceed any generated revenue, resulting in no profitability on a per-unit basis. The company holds cash reserves of $3.75 million, yet its free cash flow is negative at $-3,929,750, indicating that the company is consuming its cash reserves to fund operations and development activities without generating sufficient cash inflow to sustain itself without further capital raising. Despite the negative earnings, the company has no recorded debt, and the debt-to-equity ratio is not applicable, suggesting a balance sheet that is not leveraged but is instead reliant on equity financing to cover its substantial operating deficits. The current ratio is 1.19, which indicates that the company possesses just enough current assets to cover its current liabilities, though this buffer is fragile given the ongoing cash burn. Additionally, the Return on Equity is -92.5% and the Return on Assets is -43.5%, metrics that reveal that management's efforts have not yet generated positive returns for shareholders or asset holders, reflecting the high-risk nature of the biotechnology sector where capital is deployed for long-term R&D before commercialization.
Valuation Assessment
Exicure, Inc. presents a forward P/E ratio of -5.73, while a trailing P/E ratio is not applicable due to the lack of positive net income, a combination that implies the market is valuing the company based on non-earnings metrics such as potential future earnings or asset value rather than historical profitability. The price-to-book ratio is 7.17, which indicates that the market is pricing the company's equity at a significant premium over its book value, a common occurrence in biotechnology stocks where intangible assets like patents and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA are either not applicable or negative, with an EV/EBITDA of -2.47, suggesting that traditional valuation multiples are distorted by the company's negative earnings and lack of revenue, forcing investors to rely on qualitative assessments of the drug pipeline. The stock's price volatility is contextualized by a 52-week high of $14.94 and a 52-week low of $3.10, meaning the current market price sits somewhere within this wide range, reflecting the speculative nature of the investment. The beta value is not available, which prevents a direct comparison of the stock's volatility relative to the broader market, but the wide trading range itself suggests high sensitivity to market sentiment regarding biotechnology developments.
Growth & Income
Exicure, Inc. does not report revenue growth or earnings growth rates as these figures are not applicable given the company's lack of significant operations and negative earnings, implying that the business is not currently in a phase of scaling commercial sales or expanding profitably. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all its earnings—or rather, its capital—to reinvest into research and development rather than distributing income to shareholders. Because the earnings are negative and the payout ratio is zero, the company is unable to sustain a dividend program, and instead, it must rely on external capital markets to fund its operations and fuel future growth initiatives. Overall, the growth and income profile of Exicure, Inc. is characterized by a complete reliance on capital appreciation potential rather than income generation or historical growth metrics, making it a speculative asset suited for investors with a high tolerance for volatility and a long-term horizon for biotechnology breakthroughs.